Pathology & Laboratory Medicine

Warning message

Selective filter "Related Faculty (field_biblio_faculty) (selective)" has limited the amount of total results. Please, review you query configuration.

Publications

Filter By Faculty

Filter by Principal Investigator

2023

Barbhaiya M, Zuily S, Naden R, Hendry A, Manneville F, Amigo M-, et al. 2023 ACR/EULAR antiphospholipid syndrome classification criteria. Ann Rheum Dis. 2023;82(10):1258-1270.

Stopsack KH, Su XA, J Vaselkiv B, Graff RE, Ebot EM, Pettersson A, et al. Transcriptomes of Prostate Cancer with TMPRSS2:ERG and Other ETS Fusions. Mol Cancer Res. 2023;21(1):14-23.

Khan I, Wu S, Hudson A, Hughes C, Stryjniak G, Westblade LF, et al. A Distinct Nasal Microbiota Signature in Peritoneal Dialysis Patients. medRxiv. 2023.

Sud K, Narula N, Aikawa E, Arbustini E, Pibarot P, Merlini G, et al. The contribution of amyloid deposition in the aortic valve to calcification and aortic stenosis. Nat Rev Cardiol. 2023;20(6):418-428.

Liu A, Kremyanskaya M, Mehrazin R, Si Q, Robinson BD, Cushing MM, et al. Erythropoietin-secreting metanephric adenoma presenting as erythrocytosis. Am J Hematol. 2023;98(11):1808-1813.

Waterton K, Magro CM, Lipner SR. Nail Unit Squamous Cell Carcinoma with Onycholemmal Features: Case Report and Review of the Literature. Skin Appendage Disord. 2023;9(4):284-290.

Guadix SW, Marianayagam NJ, Weidman EK, Yuan M, Liechty B, Greenfield JP, et al. Defining Occult High-Risk Cysts of the Pineal Region: A Case Series. Oper Neurosurg (Hagerstown). 2023;24(6):572-581.

Hongo JA, de Castro GM, Menezes AP, Picorelli AC, da Silva TT, Imada EL, et al. CALANGO: A phylogeny-aware comparative genomics tool for discovering quantitative genotype-phenotype associations across species. Patterns (N Y). 2023;4(6):100728.

Karaaslan S, Dilcher TL, Abdelsayed M, Goyal A. Significant outcomes associated with high-risk human papillomavirus negative Papanicolaou tests. J Am Soc Cytopathol. 2023;12(3):189-196.

Brown-Burke F, Hwang I, Sloan S, Hinterschied C, Helmig-Mason JB, Long M, et al. PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma. Blood Adv. 2023;7(20):6211-6224.